Looking at options history for Novo Nordisk NVO we detected 8 trades. If we consider the specifics of each trade, it is ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 8 trades. If we consider the ...

The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss ...

Shares of Novo Nordisk surged 10% after promising trial results for a new weight loss drug. Meanwhile, Boeing disclosed an expected $4 billion loss for Q4 2024, reflecting ongoing challenges in ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

The most anticipated annual report in Denmark does not disappoint. Denmark’s largest company and leading pharmaceutical ...

Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

The markets are likely to show some reactions to Donald Trump’s trade war, sparked by the US imposing sweeping tariffs on ...

Novo Nordisk's Kamogelo Mmako told Spotlight: "We have not publicly announced launch timing for Rybelsus or Wegovy in South Africa." After Semaglutide, Tirzepatide is probably the next best known ...